BMY vs VRTX: fair value comparison
Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated · Updated 2026-10-19
BMY currently screens as overvalued while VRTX screens as fairly valued. Within Healthcare, VRTX currently sits closer to the top of our ranking by discount to fair value. VRTX carries the stronger quality grade.
| BMY | VRTX | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $59.12 | $510.08 |
| 12-month range | $42.60–$68.09 | $409.47–$557.96 |
| Rank by discount to fair value | #72 of 108 Healthcare | #70 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BMY fair value analysis · VRTX fair value analysis